We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q3 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (REIT) earnings release this morning:
In-line FFO
Ventas came out with normalized funds from operations (FFO) per share of $1.04, meeting the Zacks Consensus Estimate.
Results reflect improved property performance and accretive investments.
How Was the Earnings Surprise Trend?
Ventas has a decent surprise history. Before posting the in-line Q3 FFO, the company delivered positive surprises in three of the trailing four quarters. In the other occasion, the company posted in-line results. This is depicted in the graph below:
Overall, the company surpassed the Zacks Consensus Estimate by an average of 1.22% in the trailing four quarters.
Revenues Came In Higher Than Expected
Ventas posted revenues of $899.9 million, which beat the Zacks Consensus Estimate of $869.4 million. Further, it compared favorably with the year-ago number of $867.1 million.
Key Developments to Note
During the quarter, Ventas funded investments of around $80 million. It also realized approximately $570 million for the sale of 29 of its Kindred Healthcare, Inc skilled nursing facilities (SNFs). However, the company exited the quarter with reduced liquidity.
The company updated its outlook and expects its 2017 normalized FFO per share in the range of $4.13-$4.16. The mid-point of the guidance remains unchanged from the prior guidance as the Kindred SNF sale offsets improved property performance. Also, the company anticipates same-store cash net operating income growth of 2-2.5% in 2017.
What Zacks Rank Says
Ventas has a Zacks Rank #3 (Hold). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
Check back later for our full write up on this VTR earnings report!
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Ventas (VTR) Meets Q3 FFO Estimates, Updates 2017 Guidance
Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q3 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (REIT) earnings release this morning:
In-line FFO
Ventas came out with normalized funds from operations (FFO) per share of $1.04, meeting the Zacks Consensus Estimate.
Results reflect improved property performance and accretive investments.
How Was the Earnings Surprise Trend?
Ventas has a decent surprise history. Before posting the in-line Q3 FFO, the company delivered positive surprises in three of the trailing four quarters. In the other occasion, the company posted in-line results. This is depicted in the graph below:
Overall, the company surpassed the Zacks Consensus Estimate by an average of 1.22% in the trailing four quarters.
Revenues Came In Higher Than Expected
Ventas posted revenues of $899.9 million, which beat the Zacks Consensus Estimate of $869.4 million. Further, it compared favorably with the year-ago number of $867.1 million.
Key Developments to Note
During the quarter, Ventas funded investments of around $80 million. It also realized approximately $570 million for the sale of 29 of its Kindred Healthcare, Inc skilled nursing facilities (SNFs). However, the company exited the quarter with reduced liquidity.
The company updated its outlook and expects its 2017 normalized FFO per share in the range of $4.13-$4.16. The mid-point of the guidance remains unchanged from the prior guidance as the Kindred SNF sale offsets improved property performance. Also, the company anticipates same-store cash net operating income growth of 2-2.5% in 2017.
What Zacks Rank Says
Ventas has a Zacks Rank #3 (Hold). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Check back later for our full write up on this VTR earnings report!
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>